Nearly 2.5% of shares in issue sold by directors which is huge. They have put a spin on it by saying institutions want to buy shares. Although we do know a institutional investor bought a huge chunk recently.
Was concerned that Avacta’s LFT might not be up to the job with the new variants, but this Twitter article puts that to bed https://twitter.com/SharesChat/status/1363059064641630215/photo/1 Variants will spread as soon as lockdown is over as vaccines ineffective
Krok, It is always good to see a ardent critic such as yourself switch sides and have a positive outlook. So hopefully you have made the right decision and we see the price move on upwards now. Price is looking very stable at these levels fingers crossed, so we hopefully re-rate. The well results are due any day and I am just wondering if the results have been leaked which is why were getting some steady buys come through.
Bought some yesterday, let's see how it goes. Looks like a good company, debt-free and plenty of growth potential. Any idea on who the major shareholders are? I see the directors bought in 2019/2020 at 0.15 and 0.27p.
Yes any day oldholder for the test results. I think these results are less important now that we have the Arkona capacity on board this year, not a bad acquisition for $8M. Still plenty of cash to distribute or buy more companies.
There is another license issue thats been going on for years in the VAS region. I dont think anyone seems to be that interested as the courts have said they can continue to operate.